Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Down 29%, should I buy Palantir for my Stocks and Shares ISA?

Palantir Technologies has lost over a quarter of its value in the past few months. Does this make it a…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Selling for £1, are Lloyds shares still a bargain?

Lloyds shares sold for pennies for many years -- but now cost a pound. Our writer sees some strengths in…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

How much could spending just £5 a day on UK shares earn in passive income?

Sticking to UK shares in well-known companies, our writer shows how £5 a day could be used to target over…

Read more »

Dominos delivery man on skateboard holding pizza boxes
Investing Articles

Think you’re too young for a SIPP? Think again!

Is a SIPP something best left to later in working life? Not at all, according to this writer -- and…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

These 5 FTSE 100 shares all offer dividend yields well above average!

Christopher Ruane gives the lowdown on a handful of FTSE 100 shares, all yielding considerably higher than the index, that…

Read more »

Investing Articles

How to turn a Stocks and Shares ISA into £10k of annual passive income

Mark Hartley outlines a simple method of achieving a stable passive income stream from a Stocks and Shares ISA without…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 useful lessons from Warren Buffett for an investor over 40

Can Warren Buffett's long-term approach to investing still work for someone in middle age, or older? Christopher Ruane believes it…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

This UK growth share’s already doubled this year. I reckon it might just be getting going!

This UK growth share has more than doubled in a matter of weeks. Our writer thinks the market may be…

Read more »